Embryonic Stem cell
Undeveloped immature microorganisms Embryonic Stem Cell (ESCs) are pluripotent undifferentiated organisms gotten from the inward cell mass of a blastocyst, a morning phase pre-implantation embryo. Mortal uninhabited organisms arrive at the blastocyst stage 4- 5 days post treatment, when they comprise of 50- 150 cells. Uninhabited immature microorganisms of the inward cell mass are pluripotent, meaning they can separate to produce crude ectoderm.
- Pluripotency
- Primitive ectoderm
- Endoderm
- Mesoderm
Related Conference of Embryonic Stem cell
March 09-10, 2026
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
Singapore City, Singapore
June 18-19, 2026
16th International Conference on Human Genetics and Genetic Diseases
Singapore City, Singapore
June 18-19, 2026
19th International Conference on Genomics & Pharmacogenomics
Singapore City, Singapore
Embryonic Stem cell Conference Speakers
Recommended Sessions
- 3D Bio-Printing and Organ Printing
- Biomedicine
- Cancer Stem cell
- Cell and Organ Regeneration
- Clinical Trials on Stem Cell & Gene Therapy
- Diseases and Stem Cell Treatment
- Embryonic Stem cell
- Emerging Nanotechnology for Stem Cell Therapy
- Gene and Cell Therapy
- Regenerative Medicine and Therapeutics
- Scaffolds and Tissue Regeneration
- Stem Cell and Regenerative Medicine
- Stem Cell Therapy for Musculoskeletal Diseases
- Stem cells in regenerative biology
- Tissue Engineering and 3D Cell Culture
Related Journals
Are you interested in
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (Japan)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (Japan)
- Cancer Stem Cells and Oncology - Stemgen 2026 (Japan)
- Cardiovascular Regeneration - Stemgen 2026 (Japan)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (Japan)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (Japan)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (Japan)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (Japan)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (Japan)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (Japan)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (Japan)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (Japan)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (Japan)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (Japan)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (Japan)

